185 related articles for article (PubMed ID: 34848050)
1. Direct Oral Anticoagulants in Cardiac Amyloidosis-Associated Heart Failure and Atrial Fibrillation.
Mentias A; Alvarez P; Chaudhury P; Nakhla M; Moudgil R; Kanj M; Hanna M; Desai MY
Am J Cardiol; 2022 Feb; 164():141-143. PubMed ID: 34848050
[No Abstract] [Full Text] [Related]
2. [Not Available].
Oldgren J
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512140
[No Abstract] [Full Text] [Related]
3. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
[TBL] [Abstract][Full Text] [Related]
5. New oral anticoagulants for patients with nonvalvular atrial fibrillation.
Holden A; Azimi N; Forest CP
JAAPA; 2015 Nov; 28(11):28-34. PubMed ID: 26501575
[TBL] [Abstract][Full Text] [Related]
6. [Anticoagulation for patients with non-valvular atrial fibrillation].
Mizoguchi T; Yasaka M
Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
[TBL] [Abstract][Full Text] [Related]
8. [New oral anticoagulants in patients with atrial fibrillation in a urban health center].
Rodríguez Pérez L; Capilla Lozano F; Gallego Fuentes R; Buitrago F
Med Clin (Barc); 2016 Mar; 146(6):280-1. PubMed ID: 26343157
[No Abstract] [Full Text] [Related]
9. The new oral anticoagulants: Reasonable alternatives to warfarin.
Roca B; Roca M
Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
[TBL] [Abstract][Full Text] [Related]
10. [Large studies of NOAC shows good and safe stroke protection].
Hijazi Z; Oldgren J
Lakartidningen; 2015 Sep; 112():. PubMed ID: 26348046
[No Abstract] [Full Text] [Related]
11. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
[TBL] [Abstract][Full Text] [Related]
12. Novel Anticoagulants in Atrial Fibrillation: A Primer for the Primary Physician.
Mookadam M; Shamoun FE; Mookadam F
J Am Board Fam Med; 2015; 28(4):510-22. PubMed ID: 26152444
[TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years.
Tsai CT; Liao JN; Chen SJ; Jiang YR; Chen TJ; Chao TF
Eur J Clin Invest; 2021 Jun; 51(6):e13488. PubMed ID: 33420738
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation Therapy and NOACs in Heart Failure.
Thomas I; EncisoSilva J; Schlueter M; Greenberg B
Handb Exp Pharmacol; 2017; 243():515-535. PubMed ID: 28233177
[TBL] [Abstract][Full Text] [Related]
15. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
Fanikos J; Burnett AE; Mahan CE; Dobesh PP
Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818
[TBL] [Abstract][Full Text] [Related]
16. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
17. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
[TBL] [Abstract][Full Text] [Related]
18. Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.
Vaughan Sarrazin MS; Jones M; Mazur A; Cram P; Ayyagari P; Chrischilles E
J Am Coll Cardiol; 2017 Jan; 69(3):360-362. PubMed ID: 28104077
[No Abstract] [Full Text] [Related]
19. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
[TBL] [Abstract][Full Text] [Related]
20. Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
Duke Med Health News; 2014 Sep; 20(9):3. PubMed ID: 25358137
[No Abstract] [Full Text] [Related]
[Next] [New Search]
